S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

MRK Merck and Co Inc

128.80

-0.42 (-0.33%)

After Hours

Last Updated: 15:15:02

Delayed by 15 minutes

3 Best Dividend Stocks in Healthcare

http://www.fool.com/investing/general/2015/04/12/3-best-dividend-stocks-in-healthcare.aspx?source=eptadnlnk0000002

Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Merck Charts.

Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Merck Charts.

News

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Wednesday 1 May 2024 (9 hours ago) • Business Wire

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Monday 29 April 2024 (2 days ago) • Business Wire

U.S. Stocks Climb Well Off Worst Levels But Close Mostly Lower
Thursday 25 April 2024 (6 days ago) • IH Market News

Futures Pointing To Sharply Lower Open On Wall Street
Thursday 25 April 2024 (6 days ago) • IH Market News

Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings
Thursday 25 April 2024 (6 days ago) • IH Market News

Merck Announces First-Quarter 2024 Financial Results
Thursday 25 April 2024 (6 days ago) • Business Wire

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-conta
Friday 19 April 2024 (2 weeks ago) • PR Newswire (Canada)

Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
Wednesday 10 April 2024 (3 weeks ago) • IH Market News

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Thursday 4 April 2024 (4 weeks ago) • Business Wire

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Wednesday 3 April 2024 (4 weeks ago) • Business Wire

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Monday 1 April 2024 (1 month ago) • Business Wire

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Thursday 28 March 2024 (1 month ago) • Business Wire

More News Articles

Global Developments (PK)

Mullen Automotive

NaturalShrimp (QB)

FBEC Worldwide (PK)

Tonner One World (PK)

Wanderport (PK)

Branded Legacy (PK)

Moon Equity (PK)

Virexit Technologies (PK)

NioCorp Developments

BlueFire Equipment (PK)

Elite Pharmaceuticals (QB)

Impact Fusion (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions